Neurocrine Biosciences Shares Owned By Institutions vs. Number Of Shares Shorted
| NBIX Stock | USD 138.64 1.95 1.43% |
For Neurocrine Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neurocrine Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neurocrine Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neurocrine Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neurocrine Biosciences over time as well as its relative position and ranking within its peers.
Neurocrine |
Neurocrine Biosciences' Revenue Breakdown by Earning Segment
Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.512 | Earnings Share 3.75 | Revenue Per Share 22.422 | Quarterly Revenue Growth 0.247 | Return On Assets 0.118 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neurocrine Biosciences Number Of Shares Shorted vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Neurocrine Biosciences's current stock value. Our valuation model uses many indicators to compare Neurocrine Biosciences value to that of its competitors to determine the firm's financial worth.Neurocrine Number Of Shares Shorted vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Neurocrine Biosciences |
| = | 95.93 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Neurocrine Biosciences |
| = | 3.91 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Neurocrine Number Of Shares Shorted Comparison
Neurocrine Biosciences is currently under evaluation in number of shares shorted category among its peers.
Neurocrine Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Neurocrine Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neurocrine Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Neurocrine Biosciences' change in net profit over the period of time. It can combine multiple indicators of Neurocrine Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 7 M | 7.3 M | |
| Operating Income | 250.9 M | 263.4 M | |
| Income Before Tax | 332.1 M | 348.7 M | |
| Total Other Income Expense Net | 81.2 M | 85.3 M | |
| Net Income | 249.7 M | 262.2 M | |
| Income Tax Expense | 82.4 M | 86.5 M | |
| Net Income From Continuing Ops | 191 M | 200.6 M | |
| Non Operating Income Net Other | -25.2 M | -23.9 M | |
| Net Income Applicable To Common Shares | 177.7 M | 186.6 M | |
| Interest Income | 29.6 M | 31.1 M | |
| Net Interest Income | -4.6 M | -4.8 M | |
| Change To Netincome | 306.2 M | 321.6 M | |
| Net Income Per Share | 2.56 | 2.68 | |
| Income Quality | 1.56 | 1.64 | |
| Net Income Per E B T | 0.75 | 0.87 |
Neurocrine Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Neurocrine Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neurocrine Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neurocrine Biosciences' important profitability drivers and their relationship over time.
Use Neurocrine Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurocrine Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will appreciate offsetting losses from the drop in the long position's value.Neurocrine Biosciences Pair Trading
Neurocrine Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Neurocrine Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurocrine Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurocrine Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurocrine Biosciences to buy it.
The correlation of Neurocrine Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurocrine Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurocrine Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurocrine Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Neurocrine Biosciences position
In addition to having Neurocrine Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Giant Impact Thematic Idea Now
Giant Impact
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.